Skip to main content

Weather Alert

Hurricane Helene is severely impacting Quest locations across the Southeast. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational.

Hide
Quest Diagnostics

Development, Validation, and Clinical Assessment of a Liquid Chromatography-Tandem Mass Spectrometry Serum Assay for per- and Polyfluoroalkyl Substances (PFAS) Recommended by the National Academies of Science, Engineering, and Medicine (NASEM)

Development, validation, and clinical assessment of a liquid chromatography-tandem mass spectrometry serum assay for per- and polyfluoroalkyl substances (PFAS) recommended by the National Academies of Science, Engineering, and Medicine (NASEM)

Authors: Dui W, Smith MP, Bartock SH

Citation: Anal Bioanal Chem. 2024 Sep 13. doi: 10.1007/s00216-024-05519-y. Online ahead of print.

Specialties: Toxicology

Related content

Conference Presentation
Development and Validation of the 9 NASEM PFAS Analytes in Serum and NASEM Recommended Summation PFAS Results in Donor Specimens

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.